| Execution period | 60 months |
|---|
NSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,215.00
- Market cap
- ₹5,596 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 41.9×Sector 46.1×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Senores Pharmaceuticals Results Update
Senores reported Q2 FY27 revenue of ₹192 cr and EBITDA of ₹58 cr, both record highs. PAT grew 22% Y-o-Y to ₹37 cr with positive FY27 outlook.
Senores Pharmaceuticals Capacity Expansion: ₹43 Cr Investment
Senores Pharmaceuticals disclosed capacity expansion at three subsidiaries with total estimated cost of ₹43 Crore. Expansions adding ~1.5 Bn units/annum are expected by March 2027.
- Value
- ₹43.00 Cr
- Execution
- By end of March 2027
- manufacturing capacity addition (per annum)
- 1502.7 Mn units
Other other announcement announcements
All →Infronics Systems Other Announcement
Infronics Systems appointed R & A Associates as Secretarial Auditor for FY 2026-27. This is a routine statutory appointment with no financial impact.
- Execution
- FY 2026-27
Onix Solar Energy Other Announcement
Onix Solar Energy's monitoring agency reports its rights issue proceeds are fully utilised. The report covers the quarter ended 30 September 2026.
Steamhouse India Other Announcement
Steamhouse India's Reg 32 statement confirms no deviation in IPO fund utilisation from prospectus objects for the quarter ended September 30, 2026. It also discloses a rectified issue-expense figure reallocating Rs 53.5 million to general corporate purposes.
Pine Labs Other Announcement
Pine Labs Limited filed CARE Ratings' Monitoring Agency Report for the quarter ended September 30, 2026, on its IPO proceeds. The report shows no deviation from objects and no major deviations.
Sihora Industries Other Announcement
Sihora Industries reported IPO proceeds utilisation of Rs.983.87 lakh of Rs.1,056 lakh raised, to September 2026. Shareholders approved the object deviation on 17 August 2026.
Titan Company Other Announcement
Titan's employee stock option trust transferred 19,385 shares worth Rs.8.40 Crore to eligible employees after PSU exercise. The off-market transfer was disclosed under PIT Reg 7(2).
- Value
- ₹8.40 Cr